Department of Medical Biochemistry, Amsterdam UMC, Amsterdam Cardiovascular Sciences, Institute for Infection and Immunity, Amsterdam, The Netherlands.
Department of Medical Biochemistry, Amsterdam UMC, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Eur J Immunol. 2020 Nov;50(11):1643-1652. doi: 10.1002/eji.202048869. Epub 2020 Oct 25.
The nuclear receptor Nur77 is expressed in a multitude of tissues, regulating cell differentiation and homeostasis. Dysregulation of Nur77 signaling is associated with cancer, cardiovascular disease, and disorders of the CNS. The role of Nur77 in T cells has been studied for almost 30 years now. There is a clear appreciation that Nur77 is crucial for apoptosis of self-reactive T cells. However, the regulation and function of Nur77 in mature T cells remains largely unclear. In an exciting development, Nur77 has been recently demonstrated to impinge on cancer immunotherapy involving chimeric antigen receptor (CAR) T cells and tumor infiltrating lymphocytes (TILs). These studies indicated that Nur77 deficiency reduced T cell tolerance and exhaustion, thus raising the effectiveness of immune therapy in mice. Based on these novel insights, it may be proposed that regulation of Nur77 activity holds promise for innovative drug development in the field of cellular immunotherapy in cancer. In this review, we therefore summarize the role of Nur77 in T cell selection and maturation; and further develop the idea of targeting its activity in these cells as a potential strategy to augment current cancer immunotherapy treatments.
核受体 Nur77 在多种组织中表达,调节细胞分化和稳态。Nur77 信号的失调与癌症、心血管疾病和中枢神经系统疾病有关。现在已经对 Nur77 在 T 细胞中的作用进行了近 30 年的研究。人们清楚地认识到,Nur77 对于自身反应性 T 细胞的凋亡至关重要。然而,Nur77 在成熟 T 细胞中的调节和功能仍在很大程度上不清楚。在一个令人兴奋的进展中,Nur77 最近被证明影响了涉及嵌合抗原受体 (CAR) T 细胞和肿瘤浸润淋巴细胞 (TIL) 的癌症免疫疗法。这些研究表明,Nur77 缺乏减少了 T 细胞的耐受性和衰竭,从而提高了免疫治疗在小鼠中的有效性。基于这些新的见解,可以提出调节 Nur77 活性有望为癌症细胞免疫治疗领域的创新药物开发提供新的途径。在这篇综述中,我们总结了 Nur77 在 T 细胞选择和成熟中的作用;并进一步提出了靶向这些细胞中 Nur77 活性的想法,作为增强当前癌症免疫治疗的一种潜在策略。